Tested Applications
Positive FC detected in | human PBMCs |
Recommended dilution
Application | Dilution |
---|---|
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
98239-1-RR targets CD164 in FC applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Recombinant |
Type | Antibody |
Immunogen | Recombinant protein Predict reactive species |
Full Name | CD164 molecule, sialomucin |
Calculated Molecular Weight | 21kDa |
GenBank Accession Number | NM_006016.6 |
Gene Symbol | CD164 |
Gene ID (NCBI) | 8763 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Protein A purfication |
UNIPROT ID | Q04900-1 |
Storage Buffer | PBS with 0.09% sodium azide, pH 7.3. |
Storage Conditions | Store at 2 - 8°C. Stable for one year after shipment. |
Background Information
Sialomucins are a heterogeneous group of secreted or membrane-associated mucins that appear to play 2 key but opposing roles in vivo: first as cytoprotective or antiadhesive agents, and second as adhesion receptors. CD164 is a type I integral transmembrane sialomucin that functions as an adhesion receptor (PMID: 9680353)(PMID: 17077324). Sialomucin CD164 (MUC-24), also referred to multi-glycosylated core protein 24 (MGC24), is known to function as a receptor that regulates stem cell localization to the bone marrow. CD164 may play a key role in hematopoiesis by facilitating the adhesion of CD34+ cells to the stroma and by negatively regulating CD34+CD38(lo/-) cell proliferation. Important role of CD164 in in prostate cancer metastasis, promoting myogenesis and regulating myoblast migration so far have been revealed (PMID: 9763543)(PMID: 16859559)(PMID: 17077324).
Protocols
Product Specific Protocols | |
---|---|
FC protocol for CD164 antibody 98239-1-RR | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |